Krowicki Zbigniew K, Kapusta Daniel R
Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, USA.
J Pharmacol Exp Ther. 2006 Apr;317(1):446-53. doi: 10.1124/jpet.105.094441. Epub 2006 Jan 11.
Central administration of nociceptin/orphanin FQ (N/OFQ) produces bradycardia, hypotension, diuresis, and antinatriuresis in rats. Because N/OFQ peptide (NOP) receptors exist in the paraventricular nucleus (PVN) of the hypothalamus, we hypothesized that N/OFQ acts in the PVN to alter cardiovascular and renal function. To test this premise, N/OFQ (10 and 100 pmol) or artificial cerebrospinal fluid (vehicle) was microinjected into the right PVN of conscious, chronically instrumented rats infused i.v. with isotonic saline. After injection, N/OFQ, but not vehicle, dose-dependently decreased renal sympathetic nerve activity (RSNA) and increased urine flow rate. At 100 pmol, N/OFQ also decreased urinary sodium and potassium excretion and increased free water clearance. In separate groups, the diuretic response to N/OFQ injection into the PVN was blunted in chronic bilaterally renal denervated rats and abolished in intact rats continuously infused i.v. with [Arg(8)]vasopressin (60 fmol/kg/min). Finally, in other studies bilateral microinjection of the NOP receptor antagonist [Nphe(1),Arg(14),Lys(15)]N/OFQ-NH(2) (UFP-101; 300 pmol) into the PVN increased heart rate and RSNA and decreased urine flow rate without altering electrolyte excretion. Pretreatment of separate rats with UFP-101 (300 pmol, PVN) blocked the N/OFQ-evoked (100 pmol) cardiovascular, renal sympathetic nerve, and renal excretory responses. Together, these findings demonstrate that in conscious rats activation of NOP receptors in the PVN by N/OFQ produces bradycardia, renal sympathoinhibition, and water diuresis. Moreover, UFP-101 blocks a tonically active inhibitory influence of endogenous N/OFQ on central sympathetic outflow and vasopressin pathways which arise from the PVN to affect heart rate and urine output.
向大鼠中枢给药痛敏肽/孤啡肽FQ(N/OFQ)可导致心动过缓、低血压、利尿及尿钠排泄减少。由于下丘脑室旁核(PVN)中存在N/OFQ肽(NOP)受体,我们推测N/OFQ通过作用于PVN来改变心血管及肾功能。为验证这一假设,将N/OFQ(10和100皮摩尔)或人工脑脊液(溶媒)微量注射到经长期仪器植入、清醒的静脉输注等渗盐水的大鼠右侧PVN中。注射后,N/OFQ而非溶媒剂量依赖性地降低肾交感神经活动(RSNA)并增加尿流率。在100皮摩尔时,N/OFQ还减少尿钠和钾排泄并增加自由水清除率。在不同组中,慢性双侧肾去神经大鼠对向PVN注射N/OFQ的利尿反应减弱,而在持续静脉输注[精氨酸(8)]血管加压素(60飞摩尔/千克/分钟)的完整大鼠中该反应消失。最后,在其他研究中,向PVN双侧微量注射NOP受体拮抗剂[苯丙氨酸(1),精氨酸(14),赖氨酸(15)]N/OFQ-NH₂(UFP-101;300皮摩尔)可增加心率和RSNA并降低尿流率,而不改变电解质排泄。用UFP-101(300皮摩尔,PVN)预处理不同大鼠可阻断N/OFQ诱发(100皮摩尔)的心血管、肾交感神经及肾排泄反应。总之,这些发现表明,在清醒大鼠中,N/OFQ激活PVN中的NOP受体可导致心动过缓、肾交感抑制及水利尿。此外,UFP-101可阻断内源性N/OFQ对源自PVN影响心率和尿量输出的中枢交感神经传出及血管加压素途径的持续活性抑制作用。